EphB1 as a Novel Drug Target to Combat Pain and Addiction
Abstract
We have shown that the synaptic receptor protein known as EphB1 is a central player in nerve injury-induced neuropathic pain and the related pain symptoms associated with the withdrawal from opioid/morphine addiction. Our hypothesis is that postsynaptic EphB1 participates in pain through the ability of its extracellular domain to form protein-protein interactions with its presynaptic ligand, ephrin-B2, and the NR1 subunit of the postsynaptic NMDA receptor to inappropriately strengthen the synapses in the spinal cord that transmit pain signals into the brain. Our project is to carry out high-throughput screens (HTS) to identify small molecular weight drug-like compounds from a>200,000 complex library that antagonize EphB1 protein-protein interactions. While we originally set out to target the EphB1:NR1 protein-protein interaction, we changed directions in Year 2 due to technical difficulties and are now focusing on the interaction of EphB1 with ephrin-B2. We have made good progress in developing HTS for antagonists that disrupt the EphB1:ephrin-B2 interaction and already have a small number of potential lead compounds from the initial pilot test screen of an 8,000 compound subset of the main library.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2016
- Accession Number
- AD1033065
Entities
People
- Mark Henkemeyer
Organizations
- University of Texas Southwestern Medical Center